Mersana Therapeutics Inc is a clinical stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana's product candidate, XMT-1536, is... Mersana Therapeutics Inc is a clinical stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana's product candidate, XMT-1536, is in a Phase 1 clinical trial in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC, and other cancers. In addition, multiple partners are using Mersana's platform to advance their ADC pipelines. 詳細を表示
Plan to announce initial clinical data for XMT-1660 at a company event by the end of 2024 Dose escalation advancing in Phase 1 clinical trial of XMT-2056 Conference call today at 8:00 a.m. ET...
CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.06 | -2.66666666667 | 2.25 | 2.35 | 1.92 | 1331586 | 2.08851525 | CS |
4 | 0.27 | 14.0625 | 1.92 | 2.83 | 1.8 | 1439992 | 2.29830215 | CS |
12 | 0.74 | 51.0344827586 | 1.45 | 2.83 | 1.28 | 1070473 | 2.10557024 | CS |
26 | -0.19 | -7.98319327731 | 2.38 | 2.83 | 1.22 | 1199252 | 2.00609403 | CS |
52 | 0.62 | 39.4904458599 | 1.57 | 6.2801 | 1.22 | 1641896 | 2.96106913 | CS |
156 | -4.96 | -69.3706293706 | 7.15 | 9.62 | 0.8014 | 2072346 | 3.48309417 | CS |
260 | -1.31 | -37.4285714286 | 3.5 | 29.09 | 0.8014 | 1611216 | 6.40747478 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約